VIP
Also known as: Vasoactive Intestinal Peptide, Aviptadil
VIP (vasoactive intestinal peptide) is a naturally occurring signalling peptide involved in vasodilation, gut function and immune modulation. The synthetic form aviptadil is investigational and not approved for general human use in Australia.
- Category
- Gut / Vasoactive
- Reported half-life
- Reported to be very short (minutes) in circulation; not well established for synthetic forms
- Common forms
- Investigational injectable (clinical-research setting), Intranasal preparations described in research
- Research status
- Endogenous peptide widely studied in physiology. The synthetic form aviptadil is investigational and not approved for general human use in Australia.
- Last updated
- 21 June 2026
Claimed effects
The following effects are reported or claimed by users and in early research. They are not established medical facts and many are not supported by large human trials.
- Reported to act as a vasodilator in study settings
- Reported to influence gut and respiratory smooth muscle function
- Investigated for possible immune-modulating and anti-inflammatory roles
- Studied (as aviptadil) in certain respiratory research contexts
How it is reported to work
VIP is described as a 28-amino-acid neuropeptide that binds VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP and producing reported effects on blood vessels, smooth muscle and immune cells. The synthetic analogue aviptadil is proposed to mimic these actions. These descriptions come from laboratory and clinical research, not from an approved general-use therapy.
Background
VIP is a naturally occurring neuropeptide found throughout the nervous system and gut, where it is reported to relax smooth muscle, widen blood vessels and influence immune signalling. The synthetic version, aviptadil, has been explored in research. This page is educational information, not medical advice, and does not recommend use.
What the research shows
Physiology research describes VIP’s reported roles in vasodilation, gut motility and inflammation. Clinical work on aviptadil is limited and its reported effects remain investigational rather than confirmed.
| Feature | Reported status |
|---|---|
| Endogenous physiology | Well studied |
| Synthetic clinical approval | None for general use |
| Australian general-use approval | None |
What people use it for (reported)
Online, people discuss VIP and aviptadil in connection with gut, vascular and immune topics. These are reported interests and anecdotes, not validated outcomes, and should not be read as established facts.
Things to be aware of
Because aviptadil is not approved for general human use in Australia, its long-term safety is not established and product purity from grey-market sources cannot be verified. Vasoactive peptides may affect circulation.
If you have a health concern, the appropriate step is to consult a qualified healthcare professional rather than self-experimenting. This article does not endorse obtaining or using VIP or aviptadil.
Reported positives & side effects
Compiled from research and community reports. These are reported outcomes, not guarantees or medical advice, individual experiences vary widely.
Reported positives
- Reported to act as a vasodilator in study settings
- Reported interest in gut and respiratory smooth-muscle function
- Reported interest in immune-modulating and anti-inflammatory roles
- Studied (as aviptadil) in certain respiratory research contexts
Common side effects
- Reported flushing and warmth
- Reported drop in blood pressure or lightheadedness
- Reported increased heart rate
- Reported diarrhoea or gut discomfort
Rare / serious side effects
- Reported significant hypotension (low blood pressure)
- Reported chest discomfort or palpitations
- Reported allergic or hypersensitivity-type reactions
- Reported unpredictable reactions from unverified product
Reported misuse & overdose risks
What has been reported to happen with overuse, excessive dosing, or long-term misuse of VIP. Listed so you can make an informed decision, not to suggest any use is safe.
- Reported self-dosing for unproven indications without monitoring of blood pressure or heart rate
- Reported use in people with cardiovascular conditions where vasodilation may be hazardous
- Reported intranasal or injectable use of unverified grey-market product
- Reported dose escalation beyond any researched range seeking stronger effects
Reported results timeline
Roughly how long people report it takes to notice effects. A general guide from reports, not a promise, and not advice. Reported as acting per-dose with rapid vasoactive effects, while broader changes are described over weeks.
First effects
reported per-dose vasoactive sensations within minutes to hours
Noticeable change
reported subjective changes over weeks of repeated dosing
Clear results
reported over an extended period; not clinically established for general use
Commonly reported dosing & protocol
Reported figures only, NOT a recommendation or dosing advice. These are numbers people report using, compiled for education so you can make an informed decision. We do not advise anyone to take VIP. Many peptides are not approved for human use in Australia. Speak to a qualified healthcare professional.
| Route | Reported as intranasal spray or subcutaneous injection in anecdotal use |
|---|---|
| Typical reported dose | Reported around 50-100 mcg per dose |
| Frequency | Reported several times daily in anecdotal accounts; no established schedule |
| Cycle length | No established cycle length |
Commonly reported as small per-dose use (injectable or intranasal) repeated over weeks; this is reported information, not advice.
Best used with / commonly stacked with
Combinations people report using together. Reported, not recommended, stacking can increase risks.
Reported alongside it for interest in gut inflammation
Reported together for interest in gut-barrier and signalling
Reported alongside it anecdotally for gut and vascular interest
Safety notes
Aviptadil is investigational and its full safety profile is not established outside controlled studies, and it is not approved for general human use in Australia. Vasodilatory peptides can affect blood pressure and heart rate. Anyone with a health concern should consult a qualified healthcare professional.